Vacinas
Estudo de caso-controle | Estimativa da efetividade das vacinas CoronaVac e BNT162b2 em pacientes com a variante Ômicron do SARS-CoV-2
7 Fev, 2023 | 17:46h
Comentário no Twitter
The CoronaVac and BNT162b2 (Pfizer) vaccines were effective against severe outcomes due to Omicron (74-77%), but protection among older individuals in Hong Kong was more likely to wane 6 months after the second dose; boosters can bring effectiveness >90%. https://t.co/kqgwryJ1kT
— JAMA Network Open (@JAMANetworkOpen) February 3, 2023
Incidência de miocardite/pericardite após vacinação contra COVID-19 com vacina mRNA entre crianças e jovens adultos nos EUA.
17 Out, 2022 | 13:38hComunicado de imprensa: Incidence of myocarditis/pericarditis following mRNA COVID-19 vaccination among children, younger adults in the US – American College of Physicians
Comentário no Twitter (fio – clique para saber mais)
Let me me perfectly clear about the evidence for myocarditis after mRNA vaccines
1. There is a notable increased incidence, age 12-39, males, with each dose (Table)https://t.co/XXQbyeLiSP pic.twitter.com/wLTZT3fppy— Eric Topol (@EricTopol) October 12, 2022
Comentário no Twitter
Let me me perfectly clear about the evidence for myocarditis after mRNA vaccines
1. There is a notable increased incidence, age 12-39, males, with each dose (Table)https://t.co/XXQbyeLiSP pic.twitter.com/wLTZT3fppy— Eric Topol (@EricTopol) October 12, 2022
Estudo levanta preocupações sobre a efetividade da vacina contra a varíola dos macacos.
8 Set, 2022 | 14:03hStudy raises concerns about the effectiveness of the monkeypox vaccine – STAT
Estudo original (preprint): Low levels of monkeypox virus neutralizing antibodies after MVA-BN vaccination in healthy individuals – medRxiv
FDA autoriza doses de reforço atualizadas para novas variantes do COVID com vacinas da Moderna e da Pfizer.
6 Set, 2022 | 13:11hFDA authorizes updated COVID boosters from Moderna and Pfizer – CIDRAP
Comunicado de imprensa do FDA: Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose – U.S. Food & Drug Administration
Seguimento de longo prazo de um estudo randomizado | Lesões de colo do útero pré-cancerosas, causadas por tipos de HPV não preveníveis por vacina, após uso de vacina contra HPV bivalente AS04.
29 Ago, 2022 | 15:50hPrecancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial – The Lancet Oncology (link para o resumo – $ para o texto completo)
Comentário no Twitter
Virological replacement & clinical unmasking are two phenomena of interest following #HPVvaccination. We show that clinical unmasking might attenuate long-term reductions in cervical precancer following successful implementation of HPV vax programs in highly screened populations https://t.co/Z7dGQNG1kG
— Monica Sierra (@MonicaSSierra) June 14, 2022
Diretriz OMS | Determinantes comportamentais e sociais da vacinação: ferramentas e diretriz prática para alcançar um alto nível de entendimento.
23 Ago, 2022 | 17:07h
Reino Unido aprova uso da vacina atualizada da Moderna para a variante Ômicron.
22 Ago, 2022 | 14:55hUK approves updated Moderna vaccine targeting Omicron variant – Associated Press/MedicalXpress
Ver também: Covid: UK first country to approve dual-strain vaccine – BBC
M-A | Vacinação com BCG em bebês e risco de tuberculose pulmonar e extrapulmonar ao longo da vida.
16 Ago, 2022 | 13:00hComentário convidado: Infant BCG vaccination is beneficial, but not sufficient – The Lancet Global Health
Comunicado de imprensa: BCG vaccine prevents tuberculosis in young children, but not adults – Boston University School of Public Health
Comentário do autor no Twitter (fio – clique para saber mais)
1/n Our new @LancetGH study investigating BCG vaccination in infancy and tuberculosis risk is out!
Link: https://t.co/Gu469QlnFh pic.twitter.com/yRIdb2I7Zr
— Leo Martinez (@LeoMarti_EpiTB) August 9, 2022
Estudo randomizado | Segurança e imunogenicidade da vacina tifoide conjugada em crianças de 9 meses a 12 anos de idade no Malawi.
16 Ago, 2022 | 12:41hComentários:
New TCV data from Malawi highlight longer-term immune response – Coalition Against Typhoid
Conteúdos relacionados:
Randomized Trial: Efficacy Analysis of a Typhoid Conjugate Vaccine
Estudo de coorte | Incidência de síndrome torácica aguda em crianças com doença falciforme após implementação da vacina pneumocócica conjugada 13-valente.
5 Ago, 2022 | 16:06h
Comentário no Twitter
#OrigInvestigation: Reduction of acute chest syndrome incidence in children with sickle-cell disease following 13-valent pneumococcal conjugate vaccine (PCV13) implementation in France. https://t.co/MuG6T0g5FU
— JAMA Network Open (@JAMANetworkOpen) August 2, 2022